The clinical setback for the AMPLIFY-7P study, involving 144 patients with pancreatic cancer, arrived just days after B. Riley Securities maintained a bullish $27 price target on the stock. By the close of trading on June 15, the share price had plummeted to $4.08, leaving stakeholders to reconcile the discrepancy between recent analyst optimism and the company's internal data. The firm SueWallSt has launched an investigation into whether Elicio Therapeutics provided misleading information to the market regarding the viability of its primary pipeline candidate. Potential claimants are being urged to compile brokerage records as attorneys evaluate whether the company’s disclosures adequately prepared investors for the high-stakes clinical outcome.